Current Position: Product Center
Anti-TrkB hIgG4 Antibody (H4H9816P2)
Cat. No.
GM-88117AB
Size
10 μg
100 μg
1 mg
Quote
数据展示
Description️
Related products
数据展示
On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of this product is more than 95% verified by SEC-HPLC.
Description️

Species Reactivity      Human

Clone                           H4H9816P2

Source/Isotype           Human IgG4(S228P/H434R/Y435F/L445P) ,Kappa

Application                 /

Specificity                   Detects TrkB

Gene                            TrkB

Other Names              NTRK2,TRKB,GP145-TrkB

Gene ID                       4915 (human)

Background                TrkB gene (NTRK2) encodes tyrosine kinase receptor B, which belongs to the neurotrophin receptor family and plays a key role in the development, differentiation, survival and synaptic plasticity of the nervous system. Its natural ligand brain-derived neurotrophic factor (BDNF) regulates neuronal growth, differentiation and survival by activating TrkB and triggering downstream signaling pathways such as PI3K/AKT, RAS/MAPK and PLC γ. However, the aberrant activation of TrkB is closely related to the occurrence and progression of multiple malignancies, especially in solid tumors such as neuroblastoma, endometrial cancer, ovarian cancer, non-small-cell lung carcinoma, etc. , trkB is constantly activated by gene fusion, overexpression or mutation, which drives tumor cell proliferation, invasion, metastasis and anti-apoptosis. In addition, NTRK gene fusions, such as those of NTRK2 with other genes, result in sustained activation of TrkB, which drives tumor growth without ligand, becoming a driver in multiple cancers. Based on these findings, targeted therapeutic strategies against TrkB, such as TRK inhibitors (larotinib, emtrotinib, etc.) , have demonstrated therapeutic potential across cancer species, and the potential of targeting TrkB for cancer therapy has been well established, providing new therapeutic options for patients with NTRK fusion-positive tumors.

Storage                        Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.

Formulation                Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.

Endotoxin                    < 1 EU/mg, determined by LAL gel clotting assay

Related products
Anti-TrkB hIgG4 Antibody (H4H9816P2)
Cat. No.
GM-88117AB
Size
10 μg
100 μg
1 mg
Quote
数据展示
Description️
Related products
数据展示
On SDS-PAGE under reducing (R)/non-reducing(N-R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of this product is more than 95% verified by SEC-HPLC.
Description️

Species Reactivity      Human

Clone                           H4H9816P2

Source/Isotype           Human IgG4(S228P/H434R/Y435F/L445P) ,Kappa

Application                 /

Specificity                   Detects TrkB

Gene                            TrkB

Other Names              NTRK2,TRKB,GP145-TrkB

Gene ID                       4915 (human)

Background                TrkB gene (NTRK2) encodes tyrosine kinase receptor B, which belongs to the neurotrophin receptor family and plays a key role in the development, differentiation, survival and synaptic plasticity of the nervous system. Its natural ligand brain-derived neurotrophic factor (BDNF) regulates neuronal growth, differentiation and survival by activating TrkB and triggering downstream signaling pathways such as PI3K/AKT, RAS/MAPK and PLC γ. However, the aberrant activation of TrkB is closely related to the occurrence and progression of multiple malignancies, especially in solid tumors such as neuroblastoma, endometrial cancer, ovarian cancer, non-small-cell lung carcinoma, etc. , trkB is constantly activated by gene fusion, overexpression or mutation, which drives tumor cell proliferation, invasion, metastasis and anti-apoptosis. In addition, NTRK gene fusions, such as those of NTRK2 with other genes, result in sustained activation of TrkB, which drives tumor growth without ligand, becoming a driver in multiple cancers. Based on these findings, targeted therapeutic strategies against TrkB, such as TRK inhibitors (larotinib, emtrotinib, etc.) , have demonstrated therapeutic potential across cancer species, and the potential of targeting TrkB for cancer therapy has been well established, providing new therapeutic options for patients with NTRK fusion-positive tumors.

Storage                        Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw.

Formulation                Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.

Endotoxin                    < 1 EU/mg, determined by LAL gel clotting assay

Related products
Message consultation
reset
submit
Message
Message consultation
reset
submit